Capricor Therapeutics

Capricor Therapeutics

Capricor Therapeutics was founded in 2005 and operates as a clinical-stage biotechnology company from San Diego. The firm is led by CEO Linda Marbán, with scientific grounding from her husband, cardiologist Eduardo Marbán, whose lab at Cedars-Sinai pioneered the cardiosphere-derived cell technology underlying Capricor's platform. The company went public via a reverse merger in 2013. Capricor's strategy centers on developing allogeneic cell and exosome-based therapies. Its lead asset, deramiocel (CAP-1002), consists of allogeneic cardiosphere-derived cells and is in a pivotal Phase 3 trial (HOPE-3) for Duchenne muscular dystrophy-related cardiomyopathy. The firm also operates an exosome platform engineered to deliver nucleic acids and proteins, with exploratory programs in vaccinology and targeted protein degradation. The company holds a partnership with Nippon Shinyaku for the commercialization of deramiocel in the US and Japan, which provides milestone and royalty economics. The company maintains a lean infrastructure with a core team in San Diego and relies on external manufacturing partnerships. In February 2025, Capricor submitted a Biologics License Application to the FDA for deramiocel in Duchenne muscular dystrophy, seeking accelerated approval based on existing clinical data. Total headcount remains concentrated on clinical development, regulatory affairs, and platform science. Capricor's architecture diverges from typical biotech plays through its dual-platform model — one clinical-stage cell therapy with a focused rare-disease path and one earlier-stage exosome platform that serves as a horizontal drug-delivery technology. This creates two uncorrelated value drivers under a single company structure, with the exosome platform functioning almost as an embedded venture opportunity alongside the lead clinical program.